There is still a lack of experience in the perioperative strategy for esophageal cancer patients in China during the epidemic of COVID-19. In December 2022, a 59-year-old male patient with esophageal cancer was admitted to our department. He received 2 cycles of neoadjuvant therapy before surgery, and developed COVID-19 perioperatively. After treatment, the infection symptoms of the patient were improved, and the postoperative recovery was satisfactory.
Citation： ZHAO Yan, LI Hui, GU Li, YOU Bin. Treatment of COVID-19 during esophageal cancer surgery: A case report. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(7): 1074-1076. doi: 10.7507/1007-4848.202301047 Copy